Ultra-sensitive procalcitonin may help rule out bacterial infections in patients with cirrhosis

Annals of Hepatology

Volumn 13, Issue 5, 2014, Pages 541-547

  Marciano, Sebastián ^a   Haddad, Leila ^a   Martínez, Alfredo P ^b   Posadas, María L ^a   Piñero, Federico ^a   Mora, Gonzalo J ^a   Guerrero, Laura N ^b   Ridruejo, Ezequiel ^b   Mandó, Oscar G ^b   Giunta, Diego H ^a   Gadano, Adrián C ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b CEMIC   (Argentina)

Author keywords

Antibiotics; Encephalopathy; End stage liver disease; Sepsis; Surrogate markers

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLOOD SAMPLING; CELLULITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EMPYEMA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PREDICTIVE VALUE; PREVALENCE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ULTRA SENSITIVE PROCALCITONIN ASSAY; URINARY TRACT INFECTION; AGED; AREA UNDER THE CURVE; ARGENTINA; BACTERIAL INFECTIONS; BLOOD; COMPLICATION; EVALUATION STUDY; MICROBIOLOGY; MIDDLE AGED; PROGNOSIS; RISK FACTOR; UPREGULATION;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ARGENTINA; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; ROC CURVE; UP-REGULATION;

EID: 84906061828     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31254-2     Document Type: Article

References (33)

1. Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int 2004; 24: 277-80.
2. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
3. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56: S1-S12.
4. Strauss E, de Sá Ribeiro MDF. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann Hepatol 2003; 2: 41-5.
5. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
6. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
7. Rimola A, Bory F, Teres J, Perez-Ayuso RM, Arroyo V, Rodes J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463-7.
8. Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994; 20: 34-8.
9. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124: 1016-20.
10. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Munoz A, Romero G, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009; 29: 415-9.
11. Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis-Relevance of acute kidney injury and comorbidities. Liver Int 2013; 33: 220-30.
12. Chen CH, Shih CM, Chou JW, Liu YH, Hang LW, Hsia TC, Hsu WH, et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int 2011; 31: 417-24.
13. Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56.
14. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology 2009; 50: 2022-33.
15. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-82.
16. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 2001; 131: 595-602.
17. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 210-7.
18. Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004; 8: R234-R242.
19. Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol 2003; 41: 165-70.
20. Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, Papatsibas G, et al. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol 2006; 18: 525-30.
21. Spahr L, Morard I, Hadengue A, Vadas L, Pugin J. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 2001; 48: 502-5.
22. Li CH, Yang RB, Pang JH, Chang SS, Lin CC, Chen CH, Chiu TH, et al. Procalcitonin as a biomarker for bacterial infections in patients with liver cirrhosis in the emergency department. Acad Emerg Med 2011; 18: 121-6.
23. Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int 2012; 32: 603-11.
24. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RN, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
25. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
26. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-4.
27. Mandell GL, Bennet JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2010.
28. Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J 2003; 20: 453-8.
29. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 2005; 146: 347-51.
30. Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, de Lucca Schiavon L, et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol 2013; 12: 599-607.
31. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-41.
32. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52: 737-41.
33. Tito L, Rimola A, Gines P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27-31.